医

Net profit surged 349%; Sunflower Pharma is on fire

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In the first three quarters of 2026, Sunflower Pharmaceutical reported a net profit attributable to shareholders of 83.53 million yuan (+349.07% YoY) and revenue of 2.119 billion yuan (+25.81%). On the surface, this growth is striking. However, when viewed over a longer timeline, the 349% surge rests on a low base from the same period in 2025. In full-year 2025, Sunflower Pharmaceutical's revenue was 2.318 billion yuan, with a net loss attributable to shareholders of 258 million yuan. The company's annual report noted this as its first-ever operating loss since inception. Between high growth and the initial loss lies an active channel clearance, pointing to a recovery process that needs to be dissected.

The Origin of 349%: Recovery, Not Reversal

Regarding the 2025 losses, the company attributed them to a proactive choice: starting in H2 2024, it "actively reviewed downstream distributors, optimized channels, upgraded models, controlled total shipment volumes, and pushed downstream distributors and retail terminals to return inventory to reasonable levels." Reduced shipments directly suppressed revenue; the same announcement cited another reason: "significant fluctuations in upstream Chinese herbal medicine market prices, combined with a sharp decline in the company's sales volume in 2025," meant unit fixed manufacturing costs could not be diluted, keeping production costs for some products high. With old debts to clear and uncooperative costs, the 2025 financial statements were hardly pretty.

The company's characterization of this choice was straightforward: "Although it has had a direct adverse impact on the company's sales revenue and performance realization, it lays the foundation for the company's future continuous, steady, and healthy development." The cost fell in 2025, with the test period in 2026. The forecast also provided a key milestone: by the end of 2025, the review of downstream channels and retail terminals was basically complete, and business operations had basically returned to normal.

Q1 2026 serves as an intuitive sample: revenue grew 27.19% YoY, and net profit attributable to shareholders reached 110 million yuan (+93.11%). The 25.81% revenue growth in the first three quarters sits in the same range as Q1, indicating continuity in revenue recovery. Profitability tells a different story—the growth rate expanded from 93% to 349%, primarily due to the low base in the same period of 2025: when the quarter still had 57.118 million yuan in attributable net profit, it decreased quarter by quarter thereafter, making the cumulative denominator smaller and smaller, amplifying the same degree of recovery into a steeper curve.

Gross margin in the first three quarters of 2026 rose 17.21 percentage points YoY, signaling a clear repair direction; however, the mechanism was that 2025's sales contraction raised unit fixed costs, and the dilution effect rebounded after shipments recovered in 2026, rather than a systemic rise in the profit center.

Looking at non-GAAP figures provides clearer insight: non-GAAP net profit in the first three quarters of 2026 grew 160.72% YoY, less than half of the GAAP figure; non-GAAP net profit for both Q2 and Q3 single quarters was negative, with Q3 at -20.9994 million yuan, while investment net income for that quarter was 19.4004 million yuan and net profit attributable to shareholders was only 4.0647 million yuan. The book profit in the most recent quarter was largely not earned from selling medicine.

Therefore, a more accurate reading of 349% is: after channel inventory clearance, shipments and terminal sales matched again, and suppressed revenue returned to near-normal levels. It measures "how much it bounced back from the trough," not "a qualitative change in profitability."

During the 2025 loss period, Sunflower Pharmaceutical's net cash flow from operating activities remained at 575 million yuan, providing a buffer for the recovery phase. But this number should be viewed with a discount: the 2024 base was -307 million yuan; positive against negative, no matter how large the growth rate, it doesn't indicate a directional change in operational quality. A more substantial figure is from the first three quarters of 2026: operating cash flow dropped 62.96% YoY; profits turned around, but collections didn't keep up. On the R&D front, full-year 2025 R&D spending was 111 million yuan, down 10% from 2024, but since 2025 revenue fell by over 30%, the proportion of revenue spent on R&D actually rose from 3.68% to 4.79%. Although R&D investment contracted during the loss year, there was no cliff-like cut. This trade-off at least indicates that R&D expenditure was not significantly deprioritized in the company's hierarchy.

Pediatric Core Business: Stable, but with Boundaries

Sunflower Pharmaceutical's position in the pediatric Chinese medicine sector is most directly stated by the company itself: "Sales scale, product quantity, and number of large-scale single products are all at the forefront of the industry." The brand foundation is equally solid. "Little Sunflower" is already an iconic brand in the pediatric drug market, with products covering respiratory systems, digestive systems, growth supplements, health products, and other 细分 fields, forming a competitive advantage of a "golden single-product cluster." The company's annual report judges it as "the company's pediatric drug products have become traffic products in the industry market"—the word "traffic" highlights the essence of this strategy: winning through broad brand awareness and terminal coverage density, rather than relying on the absolute share of a single product. This foundation also has a price tag: disclosed in the 2025 annual report, professional institutions assessed the "Little Sunflower" brand value at 1.6422 billion yuan.

Net profit surged 349%; Sunflower Pharma is on fire

A diversified product cluster provides stability, but also means it's difficult to form an absolute advantage in a single category. The structural characteristics of the pediatric Chinese medicine market determine that this core business cannot expand infinitely. The main demand for pediatric Chinese medicines lies in scenarios like colds, cough relief, phlegm reduction, and anorexia, deeply tied to the seasonal prevalence of respiratory diseases; Sunflower's product cluster happens to concentrate in this interval, meaning its revenue curve within the year is hard to completely detach from the traction of epidemiological rhythms.

Meanwhile, competition density in the track is rising. In recent years, multiple new pediatric Chinese medicines have been approved and entered the market, with some enterprises forming concentrated single-product advantages in specific sub-categories. While Sunflower holds a leading position in brand breadth, maintaining absolute leadership in every 细分 category is unrealistic and inconsistent with the norm of a fragmented market. Brand breadth can defend market share, but it cannot defend growth rates.

The value of the core business lies in providing a stable bottom position for recovery, but its growth slope is constrained by category structure and epidemiological cycles. The revenue recovery in the first three quarters of 2026 largely involved replenishing shipment volumes that were actively suppressed in 2025 back to a normal water level, a process that inherently has a ceiling. After returning to normal, the real incremental proposition will emerge.

Where Does Increment Come From: New Products, Policies, and Unlanded Variables

Sunflower Pharmaceutical's recent actions focus on two directions: horizontal expansion of the product line and marginal changes in the policy environment, but both are still in stages where the direction is clear but the volume is small.

Since 2026, a gel patch product was approved, entering the pain management field; an enteric-coated sustained-release granule for chemical drugs was approved for registration, further enriching the product pipeline for the "One Old" strategy (elderly, chronic, and supplement product groups); applications for protection of Chinese medicine varieties in the pediatric field have been accepted by the National Medical Products Administration, and clinical research for related new indications is also underway. These varieties are unlikely to significantly pull the income statement in the short term, but they determine whether the brand can gradually form a second set of product support in directions such as digestion, pain, and elderly medications beyond respiratory scenarios.

Signals at the policy level are clearer. In May 2026, eight departments including the National Health Commission published the "Implementation Opinions on Reforming and Improving the Supply and Security Mechanism for Pediatric Drugs," explicitly stating "to effectively do a good job in protecting pediatric Chinese medicines, connecting well with the Chinese medicine variety protection system," and proposing "to increase efforts in the R&D and transformation of pediatric Chinese medicines and traditional Chinese medicine preparations in medical institutions." For Sunflower Pharmaceutical, which relies on pediatric drugs as its core, this framework provides relatively favorable institutional conditions in terms of review resources and variety protection.

But institutional conditions do not equal performance conditions. The pace of policy implementation, provincial execution details, and the actual scope of varieties covered by centralized procurement remain unlanded variables. Meanwhile, R&D density in the pediatric Chinese medicine track is rising, the pace of new products entering the market is accelerating, and competition for incremental space will not automatically ease due to policy tilts.

The 349% net profit growth rate marks the completion of a repair, not the confirmation of an expansion. Sunflower Pharmaceutical holds a verified pediatric brand trump card, returning with lighter inventory after channel clearance, and the policy environment is also moving in a direction favorable to pediatric-specific drugs. But between recovery and sustained growth lie the cycles of new product cultivation, pressure from single-product competition, and growth boundaries that are unavoidable in a market with limited capacity. The third-quarter report can illustrate the strength of the rebound, but the upcoming annual reports will reveal the quality of the rebound.

Source: Medical Research Society

The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.